Quantcast
Home > Quotes > GALT
GALT

Galectin Therapeutics Inc. Common Stock (GALT) Quote & Summary Data

$5.04
*  
0.34
7.23%
Get GALT Alerts
*Delayed - data as of Mar. 18, 2019  -  Find a broker to begin trading GALT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
11
Today's High / Low
$ 5.195 / $ 4.7067
Share Volume
423,655
50 Day Avg. Daily Volume
332,445
Previous Close
$ 4.70
52 Week High / Low
$ 9.49 / $ 3.10
Market Cap
229,573,139
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.3

Intraday Chart

Shares Traded

Share Volume:
423,655
50 Day Avg. Daily Volume:
332,445

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.38

Trading Range

The current last sale of $5.04 is 62.58% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.195 $ 9.49
 Low: $ 4.7067 $ 3.10

Company Description (as filed with the SEC)

We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. We use naturally occurring, readily-available plant products as starting material in manufacturing processes to create proprietary, patented complex carbohydrates with specific molecular weights and other pharmaceutical properties. These complex carbohydrate molecules are appropriately formulated into acceptable pharmaceutical formulations. Using these unique carbohydrate-based candidate compounds that largely bind and inhibit galectin proteins, particularly galectin-3, we are undertaking the focused pursuit of therapies for indications where galectins have a demonstrated role in the pathogenesis of a given disease.  ... More ...  



Risk Grade

Where does GALT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.71
Open Date:
Mar. 18, 2019
Close Price:
$ 5.04
Close Date:
Mar. 18, 2019


Consensus Recommendation

Analyst Info